Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Court reinstates Pfizer whistleblower suit
A Pfizer whistleblower will get his day in court. Dr. Peter Rost (photo) accused the company of illegally marketing Genotropin, a human growth hormone product; he filed suit after he lost his job (he was a VP at Pharmacia when Pfizer bought the company). Info in Rost's suit led to a $34.7 million fine against Pfizer, but a federal district court threw out his complaint.
Now, the U.S. Court of Appeals has overruled the lower court. The suit will be reinstated, and Rost will have a chance to amend it. The upshot? Rost may get a share of that $34.7 million fine, and Pfizer may be vulnerable to additional fines. The drugmaker said in a statement that it's confident it will prevail--and emphasized that it was Pharmacia that promoted Genotropin for youth, beauty, and athletic prowess.
- check out Pfizer's statement at Rost's blog
- read this Pharmalot item
Related Articles:
Pfizer leaves exec dangling. Report
Grassley: Whistleblowers, call me. Report
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


